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Introduction: The most common cause of central pontine myelinolysis is an overly rapid correction of hyponatremia,
although it can also occur in patients with any condition leading to nutritional or electrolyte stress. We report a case of
diffuse large B-cell lymphoma with central pontine myelinolysis developing at the onset of disease. To the best of our
knowledge, hematological malignancies presenting with central pontine myelinolysis have been rarely reported,
especially in previously untreated patients, as in our case report.
Case presentation: A 78-year-old Japanese woman presented to a neighborhood clinic with persistent high fever,
edema, and general weakness. Despite the absence of specific neurological findings, brain magnetic resonance imaging
showed an abnormal lesion in the central pons area of her brain (hyperintense on T2-weighted and hypointense on
T1-weighted sequences), compatible with central pontine myelinolysis. She was admitted to our emergency department
in a state of shock one month later. The results of her blood tests showed greatly elevated C-reactive protein and lactate
dehydrogenase levels. She had severe hypoalbuminemia and mild hyponatremia, and showed signs of disseminated
intravascular coagulation. Mild bilateral pleural effusion, prominent subcutaneous edema, and splenomegaly were
detected on her systemic computed tomography scan. Her body fluid cultures did not show signs of infection and her
spinal aspiration did not show pleocytosis or abnormal cells. A diagnosis of diffuse large B-cell lymphoma was made
based on the results of her bone marrow examination. As she was critically ill before the diagnosis was made, she was
treated with methylprednisolone pulse therapy, followed by systemic chemotherapy (rituximab with modified THP-COP
regimen, including cyclophosphamide, pirarubicin, vindesine, and prednisolone), which resulted in complete remission
and recovery without any neurological defects, and resolution of her abnormal findings on magnetic resonance imaging.
Conclusions: Central pontine myelinolysis is a serious condition that may result in neuropathological sequelae and
mortality, and clinicians should be aware of its potential presence in patients with malignancies.
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Central pontine myelinolysis (CPM) is a neurological
disorder caused by damage to the myelin sheath of nerve
cells in the brainstem. It is a clinically heterogeneous
disease, originally thought to occur only in the central
pons area [1, 2], and later shown to affect areas outside
the pons [3]. When demyelination involves areas outside
the pons, the disorder is referred to as either extrapon-
tine myelinolysis (EPM) or central and extrapontine
myelinolysis (CPEPM). The most common cause of* Correspondence: kawatae@kyoto2.jrc.or.jp
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mia in patients with conditions associated with nutritional
or electrolyte stress. CPEPM is sometimes associated with
poor prognosis and may cause permanent cognitive
impairment. Here, we describe the case of a patient with
malignant lymphoma presenting with CPM at the onset of
the disease, who showed complete recovery without any
sequelae.
Case presentation
A previously healthy 78-year-old Japanese woman with
mild diabetes mellitus and hypertension presented to a
neighborhood clinic with general fatigue since July, and
progressive muscle weakness and walk disturbancesrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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ical history. She complained of progressive illness and
fever in November 2012, and was diagnosed with severe
edema of the lower extremities; however, no specific
neurological abnormalities were detected except mild
muscle weakness in the lower extremities. Her blood
tests at that time showed a normal white blood cell
(WBC) count (5.2 × 109/L), mild hyponatremia (sodium
level 133mEq/mL), and elevated levels of C-reactive pro-
tein (CRP) (16.23mg/dL) and lactate dehydrogenase
(LDH) (950U/L). No abnormal findings were detected
on her ultrasound tomography or systemic computed
tomography (CT) scans. Magnetic resonance imaging
(MRI) of her brain revealed a hyperintense lesion in the
central pons area in T2-weighted imaging, diffusion-
weighted imaging (DWI), and fluid-attenuated inversion
recovery (FLAIR) imaging with no mass effect.
She was admitted to our emergency department in a
state of shock in December 2012. Her blood tests showed
greatly elevated CRP (25.25mg/dL) and LDH (1475U/L)
levels, an almost normal WBC count (9.4 × 109/L), and a
low platelet count (94 × 109/L), which decreased to 48 ×
109/L and 40 × 109/L, respectively, in the following days.
She had severe hypoalbuminemia (1.64g/dL) and mild
hyponatremia (sodium 132mEq/mL), and showed signs of
disseminated intravascular coagulation. A lumbar punc-
ture showed that her cerebrospinal fluid pressure wasFig. 1 Bone marrow specimen. Bone marrow aspiration revealed a hyperce
Hematoxylin and eosin staining (40x magnification) was (b) positive for CDwithin normal limits, with no pleocytosis, abnormal cells,
or elevation of sugar or protein. Mild bilateral pleural effu-
sion, prominent subcutaneous edema, and splenomegaly
were detected on her systemic CT scan. Her body fluid
cultures (blood, urine, sputum, and cerebrospinal fluid)
did not show signs of infection, and she tested negative
for human immunodeficiency virus infection. Her bone
marrow examination showed a hypercellular bone marrow
with numerous large lymphoma cells. A G-band analysis
revealed complex karyotypes, and immunoglobulin heavy
chain (IgH)-JH gene rearrangement was detected. Lymph-
oma cells, which were positive for CD20 and MT1 and
negative for CD3 (Fig. 1), were also present in vessels,
particularly in larger vessels, but not in capillary vessels, in
the epidermis, or dermis (Fig. 2).
She was diagnosed with stage IVB diffuse large B-cell
lymphoma (DLBCL) and identified as high risk accord-
ing to the international prognostic index score. As she
was critically ill before the diagnosis was made (she
required mechanical ventilation and central venous
catheter insertion), she was treated with methylpredniso-
lone pulse therapy, followed by systemic chemotherapy
(rituximab with modified THP-COP regimen, including
cyclophosphamide, pirarubicin, vindesine, and prednisol-
one). Despite the presence of grade 4 neutropenia, her
physical condition improved markedly after her first
course of chemotherapy, with gradual correction of herllular bone marrow with numerous large lymphoma cells. (a)
20 and (c) MT1, and (d) negative for CD3
Fig. 2 Skin specimen. Large lymphoma cells were also found in the vessels of the epidermis and dermis. Cells were observed in microvessels
(hematoxylin and eosin staining: (a) 40x, (b) 400X) but were more prominent in larger vessels ((c) 40X)
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of chemotherapy, no lymphoma cells were detected on
her bone marrow examination, and the hyperintense le-
sion in the central pons on T2/FLAIR imaging had de-
creased in size and intensity. After four courses of
chemotherapy, the hyperintense lesion was even smaller,
with no enhancement on gadolinium imaging, and after
seven courses, it was almost undetectable (Fig. 3). Her
serum sodium levels showed a slow and gradual correc-
tion: 132mEq/mL at presentation to our department,
137mEq/mL after two courses of chemotherapy, and
140mEq/mL after seven courses of chemotherapy. AFig. 3 Brain magnetic resonance scan. The hyperintense lesion in the cent
was almost undetectable after several courses of chemotherapy. (a) Before
chemotherapycomplete response was achieved and sustained after nine
courses of chemotherapy. She showed complete recovery
and was discharged without any sequelae. However, she
relapsed nine months after her last chemotherapy. She
was retreated with salvage chemotherapy and showed a
partial response, but eventually died of lymphoma five
months later.
Discussion
CPM is a neurological disease caused by damage to the
myelin sheath of nerve cells in the brainstem. It was first
described in three patients with a history of alcoholral pons in T2-weighted magnetic resonance imaging decreased and
treatment, (b) after two courses, and (c) after seven courses of
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in 1959 [2]. The defining neuropathological characteris-
tics of CPM are systemic, sharply demarcated lesions,
with selective destruction of myelin sheaths and an
absence of inflammatory infiltrates. Blood vessels are
patent, and both axons and neuronal cell bodies are gen-
erally spared. Since both the pontine and extrapontine
sites involved have a rich grey and white matter inter-
face, it has been hypothesized that rapid osmotic
changes result in endothelial injury in the more vascular
grey and white matter, inducing the release of myelinoly-
tic factors that damage the adjacent white matter [1].
MRI is more accurate than CT for the detection of
CPEPM; lesions are identified as hyperintense on
T2-weighted (including FLAIR) and hypointense on
T1-weighted MRI sequences with no mass effect. Early
DWI changes are another common finding [4, 5]. The
most common cause of CPEPM is an overly rapid
correction of hyponatremia in patients with conditions
leading to nutritional or electrolyte stress, such as alco-
holism, liver disease, immunosuppression, malnourish-
ment, gastrointestinal diseases with acute electrolyte
abnormalities, syndrome of inappropriate antidiuretic
hormone secretion, renal disease, cancer, pregnancy, and
high-endurance exercise [3, 6, 7].
Although the exact pathophysiology of CPEPM is not
completely understood, a rapid increase in serum tonicity
in patients with severe hyponatremia who have made intra-
cellular adaptations to hypotonicity is widely recognized as
the underlying problem. The clinical presentation varies
among patients, with some showing no obvious neuro-
logical symptoms and only abnormal MRI findings, and
others showing a combination of neuropsychiatric (such as
emotional lability, disinhibition, and other bizarre behav-
iors) and neurologic (such as confusion, impaired cognition,
dysarthria, dysphasia, gait instability, weakness or paralysis,
and generalized seizures) symptoms [1, 8, 9]. The extent of
radiologic signal abnormality or the severity of hyponatre-
mia may not be associated with clinical outcomes. Serial
brain imaging is important in suspicious cases because a
substantial proportion of patients have normal findings on
initial MRI scans [10]. The outcome of patients with
CPEPM is traditionally reported as poor; however, several
studies have shown that this is not inevitable. A retrospect-
ive study conducted by Graff-Radford et al. reported a
favorable outcome in 60% of patients, and an overall
mortality of 8% in the acute setting [10]. Similarly, in a large
series of 34 patients with CPM, 65% of patients achieved a
good or moderate outcome (no functional deficit or inde-
pendence despite minor deficits), and 27% showed a poor
outcome, including a 6% mortality rate [11]. The increasing
availability of MRI, which facilitates early diagnosis, and
improvements in intensive care treatments are likely con-
tributing factors to the noted improvements in outcomes.Conclusions
Our case report describes a case of a woman who pre-
sented with an abnormal lesion in the central pons area
(hyperintense in T2-weighted, DWI, and FLAIR imaging,
and hypointense in T1-weighted imaging) compatible
with CPM at the first onset of DLBCL. Her serum so-
dium level was stable before and after the onset of CPM.
Lymphoma cells were not detected in her cerebrospinal
fluid, and her brain MRI showed neither mass effect nor
gadolinium-enhanced lesions. In the absence of patho-
logical brain specimens at the time of diagnosis, other
diagnostic possibilities should be considered. However,
in our patient, the lack of abnormal cerebrospinal fluid
findings, the absence of enhancement, and the extremely
localized lesion made the diagnosis of intracranial
involvement of DLBCL difficult.
To the best of our knowledge, few reports have de-
scribed cases of hematological malignancies presenting
with CPM, especially in previously untreated patients,
such as the present case [12–14]. In these reports, patho-
logical specimens were inaccessible, and the diagnosis of
CPM rested on imaging studies alone, similar to our case.
Although the cause of CPM was not fully determined, the
underlying chronic mild hyponatremia and severe hypoal-
buminemia caused by the lymphoma were possible trig-
gers of CPM in our patient. She achieved complete
response of her lymphoma, and no neurological symp-
toms or sequelae were observed after several courses of
chemotherapy. However, CPEPM is a severe and some-
times preventable condition that can result in serious
neuropathological sequelae and even death. As the eti-
ology of CPEPM remains unclear and effective treatment
strategies have not been developed, clinicians should be
aware of this condition in patients with malignancies, even
at first diagnosis, because nutritional and electrolyte stress
may increase the vulnerability of these patients.Consent
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